Health Care VC Waiting for Stem Cell Market to Grow
13:13 | 
Despite President Bush’s veto of the embryonic stem cell bill almost two months ago, many venture capitalists consider the stem cell market to be viable… though just not yet for some investors. When and why will a venture capitalist invest in a stem cell company? How does the venture industry view the stem cell controversy? Jennifer Jones of PodTech.net talks with Dr. Edgar Engleman, managing partner of Vivo Ventures, and probes their investment strategy and perspective today.
Tags: Dr. Edgar Engleman, Vivo Ventures
Leave a Comment
Our Client Shows
Upcoming Events
Additional Sites
Contact Info:
Press:
pr@podtech.net
Sales:
sales@podtech.net
Feedback:
feedback@podtech.net
Privacy Policy
PodTech Network is committed to protecting your online privacy while providing you with the most useful and enjoyable Web experience possible.
Terms of Use
Copyright ©2008 PodTech.net. All rights reserved. Modified: Sat, 06 Sep 2008 23:56:03 -0700
